Table 1 Demographic and clinical characteristics of the 38 leprosy patients according to aPL positivity or negativity on sera collected in 2010/2011
Variables | Serum aPL (2010/2011 collected sera) | p | |||||
|---|---|---|---|---|---|---|---|
Negative | Positive | Total | |||||
n | % | n | % | N | % | ||
Gender | 0.670* | ||||||
Male | 5 | 83.3% | 23 | 71.9% | 28 | 73.7% | |
Female | 1 | 16.7% | 9 | 28.1% | 10 | 26.3% | |
Age | 37.0 ± 18.2 | 48.1 ± 16.0 | 46.3 ± 16.6 | 0.075** | |||
Length of treatment | 81.2 ± 18.3 | 77.4 ± 36.5 | 80.0 ± 34.1 | 0.389** | |||
Clinical presentations | 0.081* | ||||||
BT | 1 | 16.7% | 8 | 25.0% | 9 | 23.7% | |
BB | 2 | 33.3% | 1 | 3.1% | 3 | 7.9% | |
BV | 2 | 33.3% | 7 | 21.9% | 9 | 23.7% | |
LL | 1 | 16.7% | 16 | 50.0% | 17 | 44.7% | |
Reactional episodes | 1* | ||||||
Present | 0 | 0.0% | 1 | 3.1% | 3 | 7.9% | |
Absent | 6 | 100.0% | 31 | 96.9% | 35 | 92.1% | |
Current reactional episodes | 1* | ||||||
Present | 1 | 16.7% | 3 | 9.4% | 4 | 10.5% | |
Absent | 5 | 83.3% | 29 | 90.6% | 34 | 89.5% | |
Medication | 0.188* | ||||||
No | 5 | 83.3% | 15 | 46.9% | 20 | 52.6% | |
Yes | 1 | 16.7% | 17 | 53.1% | 18 | 47.4% | |
Prednisone | 0.278* | ||||||
No | 0 | 0.0% | 4 | 23.5% | 4 | 22.2% | |
Yes | 1 | 100.0% | 13 | 76.5% | 14 | 77.8% | |
Thalidomide | 0.387* | ||||||
No | 0 | 0.0% | 6 | 35.3% | 6 | 33.3% | |
Yes | 1 | 100.0% | 11 | 64.7% | 12 | 66.7% | |